HUTCHMED (CHINA) LIMITED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of over 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed. For more information, please visit: www.hutch med.com or follow us on LinkedIn.
HUTCHMED (CHINA) LIMITED
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2000-01-01
Address:
Kowloon City, Kowloon, Hong Kong
Country:
Hong Kong
Website Url:
http://www.hutch-med.com
Total Employee:
1001+
Status:
Active
Contact:
+85221218200
Total Funding:
220.2 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS COVID-19 Proofpoint CSC Global DNS
Similar Organizations
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
YS Biopharma
YS Biopharma is a global, fully integrated bio-pharmaceutical company.
Current Employees Featured
Mr. Johnny Cheng Executive Director and Chief Financial Officer @ HUTCHMED (China) Limited
Executive Director and Chief Financial Officer
Simon To Executive Director and Chairman @ HUTCHMED (China) Limited
Executive Director and Chairman
2006-04-01
Dr. Weiguo Su SVP @ HUTCHMED (China) Limited
SVP
Founder
Stock Details
Investors List
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board investment in Post-IPO Equity - HUTCHMED (China) Limited
General Atlantic
General Atlantic investment in Post-IPO Equity - HUTCHMED (China) Limited
SBCVC
SBCVC investment in Venture Round - HUTCHMED (China) Limited
Mitsui & Co
Mitsui & Co investment in Venture Round - HUTCHMED (China) Limited
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-03 | HUTCHMED announces retirement of CEO and appointment of new CEO |
Official Site Inspections
http://www.hutch-med.com Semrush global rank: 2.57 M Semrush visits lastest month: 6.83 K
Unable to get host informations!!!
More informations about "HUTCHMED (China) Limited"
Research and Development - HUTCHMED
Fully-fledged Research, Development and Regulatory organization. Our comprehensive drug discovery and development operation covers chemistry; biology; pharmacology; toxicology; …See details»
Events, Circulars & Forms - HUTCHMED
Chi-Med; Events, Circulars & Forms | Corporate presentations; Previous Article | Next Article. Corporate presentations, Event, Presentations | 10 Jan 2025 Corporate Presentation for …See details»
HUTCHMED (China) Limited - Crunchbase Company …
Center of which is a team of over 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into …See details»
HUTCHMED - LinkedIn
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and …See details»
HUTCHMED - LinkedIn
A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs …See details»
HUTCHMED: Culture - LinkedIn
A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now ...See details»
Hutchmed - Overview, News & Similar companies | ZoomInfo.com
Hutchmed contact info: Phone number: (212) 250-9100 Website: www.chi-med.com What does Hutchmed do? HUTCHMED is an innovative, commercial-stage biopharmaceutical company …See details»
HUTCHMED Employee Directory, Headcount & Staff | LeadIQ
A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs …See details»
Hutchmed - eqtgroup.com
Dec 13, 2024 HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and …See details»
Hutchmed | European Clinical Trials Information Network
Over the years, Hutchmed has grown through a series of mergers and acquisitions, including the acquisition of Chi-Med, a UK-based biotech company, in 2006. The company has also …See details»
Events, Presentations & Circulars - HUTCHMED
United Kingdom (Toll-Free) 0800-026-1542: United Kingdom (Toll) +44 203-194-0569: United States (Toll-Free) 1855-824-5644: United States (Toll) +1 646-722-4977See details»
HUTCHMED (China) Limited - Contacts, Employees, Board
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company.See details»
HUTCHMED (China) Ltd. (和黄医药（中国）有限公司) - 药物管线_ …
Herein we describe the medicinal chemistry efforts that led to the discovery of the clinical-staged Syk inhibitor sovleplenib (41) via a structure-activity relationship investigation and …See details»
HUTCHMED (China) Limited - Funding, Financials, Valuation
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
HUTCHMED Announces NMPA Full Approval for ORPATHYS® …
1 hour ago — Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and …See details»
Change of Company Name - hutch-med.com
May 4, 2021 A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two …See details»
HUTCHMED Announces NMPA Full Approval for - GlobeNewswire
1 hour ago Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com Ben Atwell / Alex Shaw +44 …See details»
HUTCHMED Announces NMPA Full Approval for ORPATHYS® …
1 hour ago N Engl J Med. 2018;378(2):113-125. 12: Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629-640. 13: …See details»
News & Presentations - HUTCHMED
Jul 28, 2021 A dedicated organization of over 1,300 personnel. has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first …See details»
50 years of doing hard things | Fred Hutchinson Cancer Center
5 days ago Founded at the onset of Fred Hutch’s transition to a divisional structure in late 1981, the Basic Sciences Division brought together scientists seeking to understand the fundamental …See details»